BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, González-Gay MÁ. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev 2021;20:102830. [PMID: 33887489 DOI: 10.1016/j.autrev.2021.102830] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Albrecht K, Strangfeld A, Marschall U, Callhoff J. Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020. RMD Open 2023;9. [PMID: 36669830 DOI: 10.1136/rmdopen-2022-002777] [Reference Citation Analysis]
2 Song YJ, Cho SK, Kim H, Kim HW, Nam E, Choi CB, Kim TH, Jun JB, Bae SC, Yoo DH, Sung YK. Factors associated with selection of targeted therapy in patients with rheumatoid arthritis. PLoS One 2023;18:e0280234. [PMID: 36626396 DOI: 10.1371/journal.pone.0280234] [Reference Citation Analysis]
3 Razmjou AA, Wang JM, Shahbazian A, Reddy S, Charles-Schoeman C. Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis. Clin Rheumatol 2023;42:75-82. [PMID: 36138190 DOI: 10.1007/s10067-022-06375-w] [Reference Citation Analysis]
4 Temmoku J, Miyata M, Suzuki E, Sumichika Y, Saito K, Yoshida S, Matsumoto H, Fujita Y, Matsuoka N, Asano T, Sato S, Watanabe H, Migita K. Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis. PLoS ONE 2022;17:e0274775. [DOI: 10.1371/journal.pone.0274775] [Reference Citation Analysis]
5 Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis 2022;14:1759720X221114101. [PMID: 35991524 DOI: 10.1177/1759720X221114101] [Reference Citation Analysis]
6 Karassa FB, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich A. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. PLoS ONE 2022;17:e0272327. [DOI: 10.1371/journal.pone.0272327] [Reference Citation Analysis]
7 Ng KH, Chen DY, Lin CH, Chao WC, Chen HH. Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan. RMD Open 2022;8:e002343. [PMID: 35995491 DOI: 10.1136/rmdopen-2022-002343] [Reference Citation Analysis]
8 Molina-Molina M, Castellví I, Valenzuela C, Ramirez J, Rodríguez Portal JA, Franquet T, Narváez J. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022. [PMID: 35912842 DOI: 10.1080/17476348.2022.2107508] [Reference Citation Analysis]
9 Mena-vázquez N, Rojas-gimenez M, Fuego-varela C, García-studer A, Perez-gómez N, Romero-barco CM, Godoy-navarrete FJ, Manrique-arija S, Gandía-martínez M, Calvo-gutiérrez J, Morales-garrido P, Mouriño-rodriguez C, Castro-pérez P, Añón-oñate I, Espildora F, Aguilar-hurtado MC, Hidalgo Conde A, Arnedo Díez de los Ríos R, Cabrera César E, Redondo-rodriguez R, Velloso-feijoo ML, Fernández-nebro A. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease. Biomedicines 2022;10:1480. [DOI: 10.3390/biomedicines10071480] [Reference Citation Analysis]
10 Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med 2022. [PMID: 35695895 DOI: 10.1080/17476348.2022.2089116] [Reference Citation Analysis]
11 Wilson TM, Solomon JJ, Demoruelle MK. Treatment approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pharmacol 2022;65:102245. [PMID: 35662004 DOI: 10.1016/j.coph.2022.102245] [Reference Citation Analysis]
12 Laria A, Lurati AM, Zizzo G, Zaccara E, Mazzocchi D, Re KA, Marrazza M, Faggioli P, Mazzone A. Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Front Med 2022;9:837133. [DOI: 10.3389/fmed.2022.837133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen N, Diao C, Gao J, Zhao D. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152004] [Reference Citation Analysis]
14 Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 2022;:103056. [PMID: 35121155 DOI: 10.1016/j.autrev.2022.103056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
15 Karassa FB, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich A. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses.. [DOI: 10.1101/2022.01.25.22269807] [Reference Citation Analysis]
16 Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 2022;101:e28501. [PMID: 35029907 DOI: 10.1097/MD.0000000000028501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Atzeni F, Siragusano C, Gómez-puerta JA. Interstitial lung disease and rheumatoid arthritis. Handbook of Systemic Autoimmune Diseases 2022. [DOI: 10.1016/b978-0-323-91083-5.00010-4] [Reference Citation Analysis]
18 Comes A, Sgalla G, Perrotta A, Richeldi L. Advances with pharmacotherapy for the treatment of interstitial lung disease. Expert Opin Pharmacother 2021;:1-13. [PMID: 34907821 DOI: 10.1080/14656566.2021.2016697] [Reference Citation Analysis]
19 Yamakawa H, Ogura T, Kameda H, Kishaba T, Iwasawa T, Takemura T, Kuwano K. Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). J Clin Med 2021;10:3806. [PMID: 34501253 DOI: 10.3390/jcm10173806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
20 Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, Alqalyoobi S, Zeki AA, Leung PS, Shuai Z. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Front Immunol 2021;12:684699. [PMID: 34163483 DOI: 10.3389/fimmu.2021.684699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]